Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?

Blood reviews - 1 Nov 2020

Megías-Vericat Juan Eduardo, Ballesta-López Octavio, Barragán Eva, Martínez-Cuadrón David, Montesinos Pau

Abstract excerpt

Dysregulation of tyrosine kinases (TKs) may play a role in leukemogenesis by promoting survival and proliferation of acute myeloid leukemia (AML) cells. In AML, the main TKs mutations are produced in Fms-like tyrosine kinase 3 (FLT3), KIT and Janus kinase (JAK) genes, and with less frequency in BCR-ABL. The striking results with TK Inhibitors (TKIs) therapy in BCR-ABL1 chronic myeloid leukemias has paved the way...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Molecular Targeted Therapy

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 32147087
DOI: 10.1016/j.blre.2020.100675

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?PMID 32147087Read ↗

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review.Semantic proximity Read ↗

An Overview of Targeted Therapies in Acute Myeloid LeukemiaSemantic proximity Read ↗

Strategies targeting FLT3 beyond the kinase inhibitors.Semantic proximity Read ↗

Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

Molecular targeted therapy in acute myeloid leukemia.Semantic proximity Read ↗

Advances in the pathogenesis of FLT3 -mutated acute myeloid leukemia and targeted treatments.Semantic proximity Read ↗

Emerging treatments in acute myeloid leukemia: current standards and unmet challenges.Semantic proximity Read ↗

[Molecular targeted therapy for acute myeloid leukemia].Semantic proximity Read ↗

Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?Semantic proximity Read ↗

FLT3 inhibitors: clinical potential in acute myeloid leukemiaSemantic proximity Read ↗

Treatment of Acute Myeloid Leukemia in the Era of Genomics—Achievements and Persisting ChallengesSemantic proximity Read ↗

Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.